Phase Ib Trial Evalutes Glofitamab Plus Pola-R-CHP in DLBCL

By Cecilia Brown, Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA - Last Updated: June 5, 2023

Michael Dickinson, MBBS, DMedSc, of the Peter MacCallum Cancer Centre, discusses a phase Ib study of glofitamab plus pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Dr. Dickinson and colleagues presented the research at the 2023 American Society of Clinical Oncology Annual Meeting.

In this video, Dr. Dickinson outlines the rationale behind testing the combination in patients with previously untreated DLBCL, the study’s key efficacy and safety findings, and the next steps with the research.

Post Tags:ASCO2023
Editorial Board